Related Experiment Videos
Growth factor receptor kinase inhibitors: recent progress and clinical impact
1Bayer Research Center, Bayer Corporation, Pharmaceutical Division, 400 Morgan Lane, West Haven, CT 06516, USA. jacques.dumas.b@bayer.com
Current Opinion in Drug Discovery & Development
|December 1, 2001
Abstract:
Inhibition of growth factor receptor kinases is one of the most promising therapeutic approaches for the treatment of cancer. This review focuses on the most recent progress in this area, and gives an overview of the compounds currently in the clinic, as well as key preclinical analogs.
Insights
Targeting growth factor receptor kinases offers a promising cancer treatment strategy. This review highlights recent advancements in clinical and preclinical kinase inhibitors for cancer therapy.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Growth factor receptor kinases play a crucial role in cancer cell proliferation and survival.
- Targeting these kinases is a validated therapeutic strategy in oncology.
- Numerous small molecules and biologics have been developed to inhibit these targets.
Purpose of the Study:
- To provide a comprehensive overview of recent advancements in the inhibition of growth factor receptor kinases for cancer treatment.
- To summarize the current clinical landscape of kinase inhibitors.
- To highlight promising preclinical analogs in development.
Main Methods:
- Literature review of recent scientific publications and clinical trial data.
- Analysis of drug development pipelines for kinase inhibitors.
- Synthesis of information on efficacy, safety, and mechanisms of action.
Main Results:
- Several kinase inhibitors are approved and widely used in cancer treatment.
- A growing number of preclinical compounds show significant promise.
- Emerging targets and novel inhibition strategies are continually being explored.
Conclusions:
- Inhibition of growth factor receptor kinases remains a cornerstone of modern cancer therapy.
- Continued research into novel inhibitors and combination strategies is essential.
- The field is rapidly evolving, offering new hope for cancer patients.